T0	Interventions 48 58	ipilimumab
T1	Interventions 667 872	received open-label ipilimumab (10 mg/kg every 3 weeks for four doses) and were randomized to receive concomitant blinded prophylactic oral budesonide (9 mg/d with gradual taper through week 16) or placebo
T2	Interventions 1076 1082	genes.
T3	Interventions 1083 1093	Ipilimumab
T4	Interventions 1530 1553	Prophylactic budesonide